Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

Overview Data source: UniProt

Official Gene Symbol Other Aliases
LARP1B LARP2
Sequence Length (AA) Molecular Weight (Da)
914 105322
Protein Name
La-related protein 1B
Sources
UniProt
PhosphoSitePlus ®
GeneCards
Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MENWPTPSEL VNTGFQSVLS QGNKKPQNRK EKEEKVEKRS NSDSKENRET
60 70 80 90 100
KLNGPGENVS EDEAQSSNQR KRANKHKWVP LHLDVVRSES QERPGSRNSS
110 120 130 140 150
RCQPEANKPT HNNRRNDTRS WKRDREKRDD QDDVSSVRSE GGNIRGSFRG
160 170 180 190 200
RGRGRGRGRG RGRGNPRLNF DYSYGYQEHG ERTDQPFQTE LNTSMMYYYD
210 220 230 240 250
DGTGVQVYPV EEALLKEYIK RQIEYYFSVE NLERDFFLRG KMDEQGFLPI
260 270 280 290 300
SLIAGFQRVQ ALTTNLNLIL EALKDSTEVE IVDEKMRKKI EPEKWPIPGP
310 320 330 340 350
PPRSVPPTDF SQLIDCPEFV PGQAFCSHTE SAPNSPRIGS PLSPKKNSET
360 370 380 390 400
SILQAMSRGL STSLPDLDSE PWIEVKKRHQ PAPVKLRESV SVPEGSLNQL
410 420 430 440 450
CSSEEPEQEE LDFLFDEEIE QIGRKNTFTD WSDNDSDYEI DDQDLNKILI
460 470 480 490 500
VTQTPPYVKK HPGGDRTGTH MSRAKITSEL AKVINDGLYY YEQDLWMEED
510 520 530 540 550
ENKHTAIKQE VENFKKLNLI SKEQFENLTP ELPFEPNQEV PVAPSQSRQG
560 570 580 590 600
GVQGVLHIPK KDLTDELAQK LFDVSEITSA AMVHSLPTAV PESPRIHPTR
610 620 630 640 650
TPKTPRTPRL QDPNKTPRFY PVVKEPKAID VKSPRKRKTR HSTNPPLECH
660 670 680 690 700
VGWVMDSRDR GPGTSSVSTS NASPSEGAPL AGSYGCTPHS FPKFQHPSHE
710 720 730 740 750
LLKENGFTQQ VYHKYRRRCL SERKRLGIGQ SQEMNTLFRF WSFFLRDHFN
760 770 780 790 800
KKMYEEFRQL AWEDAKENYR YGLECLFRFY SYGLEKKFRR EIFQDFQEET
810 820 830 840 850
KKDYESGQLY GLEKFWAYLK YSQSKTQSID PKLQEYLCSF KRLEDFRVDP
860 870 880 890 900
PISDEFGRKR HSSTSGEESN RHRLPPNSST KPPNAAKPTS TSELQVPINS
910 914
PRRNISPESS DNSH

Data source: UniProt


Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt



Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-1030 Collapse assay details

Data source: Panorama

Official Gene Symbol
LARP1B
Peptide Modified Sequence
GLSTS[+80.0]LPDLDSEPWIEVK
Modification Type
Phospho (ST)
Protein - Site of Modification
363
Peptide - Site of Modification
5
Peptide Start
359
Peptide End
376
CPTAC ID
CPTAC-1030
Peptide Molecular Mass
2,064.9657
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
IMAC
Matrix
cell lysate
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Kennedy JJ, Yan P, Zhao L, Ivey RG, Voytovich U, Moore HD, Lin C, Pogosova-Agadjanyan EL, Stirewalt DL, Reding KW, Whiteaker JR, Paulovich AG. Immobilized metal affinity chromatography coupled to multiple reaction monitoring enables reproducible quantification of phospho-signaling. Molecular and Cellular Proteomics. mcp.O115.054940


Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTrap 5500 (Sciex)
Internal Standard
synthetic peptide
Peptide Standard Purity
Crude
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
nanoLC-2D (Eksigent)
Column Packing
ChromXP C18-CL, 3 µm, 120 Å
Column Dimensions
75 µm x 15cm
Flow Rate
300 nL/min

Chromatograms

Data source: Panorama


Response Curves

Data source: Panorama

Retrieving Data

Loader

Repeatability

Data source: Panorama

  Average intra-assay CV
(within day CV)
Average inter-assay CV
(between day CV)
Total CV
equation
n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y6 (1+) 30.4 16.7 10.7 43 56.3 21.2 52.7 58.7 23.7 11 18 13
y8 (1+) 65.6 28.3 16 57.9 55.2 29.4 87.5 62 33.5 11 18 13
y9 (1+) 41 33.8 25.7 50.8 70.1 25 65.3 77.8 35.9 11 18 13
sum 20.5 19.1 9.8 20.9 56.5 21.3 29.3 59.6 23.4 11 18 13


Additional Resources and Comments